ReviewExpert opinion on drug discovery2014
Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.
Review in Expert opinion on drug discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers.Human psychopharmacology · 2018Trial
- Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.Experimental and clinical psychopharmacology · 2018Trial
- IL-6 Expression and the Confidence Interval-Based Estimation of Relevance (CIBER) Help Identify Persistent Inflammation and Cognitive Parameters of Executive Dysfunction in the Withdrawal Phase of Male Polydrug Abusers.Healthcare (Basel, Switzerland) · 2025Article
- Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.Physiology & behavior · 2024Review
- Two-Hour Nicotine Withdrawal Improves Inhibitory Control Dysfunction in Male Smokers: Evidence from a Smoking-Cued Go/No-Go Task ERP Study.Neuropsychiatric disease and treatment · 2024Article
- Applying network analysis to understand the relationships between impulsivity and social media addiction and between impulsivity and problematic smartphone use.Frontiers in psychiatry · 2022Article
- New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.International journal of molecular sciences · 2021Review
- HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study).AIDS and behavior · 2021Article
- Chronic Lorcaserin Treatment Reverses the Nicotine Withdrawal-Induced Disruptions to Behavior and Maturation in Developing Neurons in the Hippocampus of Rats.International journal of molecular sciences · 2021Article
- Two-Hour Tobacco Abstinence Has No Effect on Cognitive Control in Male Patients With Nicotine Dependence: An ERP Study.Frontiers in psychiatry · 2020Article
- The Role of Cognitive Control in the Self-Regulation and Reinforcement of Smoking Behavior.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Review
- Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse.Molecular neuropsychiatry · 2019Review
- A cognitive model-based approach to testing mechanistic explanations for neuropsychological decrements during tobacco abstinence.Psychopharmacology · 2018Article
- Cognitive Effects of Nicotine: Recent Progress.Current neuropharmacology · 2018Review
- Paternal cocaine taking elicits epigenetic remodeling and memory deficits in male progeny.Molecular psychiatry · 2017Article
- The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.Journal of neurovirology · 2017Article
- Nicotine withdrawal-induced inattention is absent in alpha7 nAChR knockout mice.Psychopharmacology · 2017Article
- Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283.Psychopharmacology · 2017Article
- Can repetitive mental simulation of smoking engender habituation?Experimental and clinical psychopharmacology · 2016Article
- Use of an automated mobile application to assess effects of nicotine withdrawal on verbal fluency: A pilot study.Experimental and clinical psychopharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionCurrent FDA-approved smoking cessation pharmacotherapies have limited efficacy and are associated with high rates of relapse. Therefore, there is a clear need to develop novel antismoking medications. Nicotine withdrawal is associated with cognitive impairments that predict smoking relapse. It has been proposed that these cognitive deficits are a hallmark of nicotine withdrawal that could be targeted in order to prevent smoking relapse. Thus, pharmacotherapies that increase cognitive performance during nicotine withdrawal may represent potential smoking cessation agents. AREAS COVERED: The authors review the clinical literature demonstrating that nicotine withdrawal is associated with deficits in working memory, attention and response inhibition. They then briefly summarize different classes of compounds and strategies to increase cognitive performance during nicotine withdrawal. Particular emphasis has been placed on translational research in order to highlight areas for which there is strong rationale for pilot clinical trials of potential smoking cessation medications. EXPERT OPINION: There is emerging evidence that supports deficits in cognitive function as a plausible nicotine withdrawal phenotype. The authors furthermore believe that the translational paradigms presented here may represent efficient and valid means for the evaluation of cognitive-enhancing medications as possible treatments for nicotine dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.